BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
Provided By GlobeNewswire
Last update: Oct 29, 2025
PALO ALTO, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced its financial results for the third quarter ended September 30, 2025, and provided business updates.
Read more at globenewswire.com
